Persistence with osteoporosis medication among newly-treated osteoporotic patients

摘要: Low persistence with osteoporosis medication is associated higher fracture risk. Previous studies estimated that 1-year low. Our aim was to study among patients long-term follow-up (to 5 years). The InterAction Database (IADB) used analyze of 8610 Dutch initiating drugs between 2003 and 2011. Drugs under were alendronate, risedronate, ibandronate, etidronate, raloxifene strontium ranelate. Cumulative rates calculated after different time frames (3 months–5 years) using survival analysis. Multivariate Cox proportional hazard analyses identify determinants non-persistence. Furthermore, switching persistent who initiated bisphosphonate therapy analyzed. Persistence 70.7 % (95 CI, 69.7–71.7), 58.5 57.4–59.6 %), 25.3 24.1–26.5) 6 months, 1 years, respectively. Determinants risk non-persistence within the first year daily dosing regimen [HR, 1.76 1.46–2.14)], age <60 years 1.26 1.19–1.34)] use glucocorticoids 1.16 1.07–1.26)]. Monthly schedule generic brands alendronate did not show a significant association Approximately 4.0 weekly or risedronate switched therapy. Because low strongly risk, interventions improve are recommended. This identified several patient groups in whom such may be most relevant.